The Diabetes and Chronic Kidney Disease program aims to slow progression of CKD leading to end-stage renal disease and other diabetes related complications.
The aims (below) are achieved by partnering with the patient/whanau, sharing matauranga/knowledge, improving self-management skills and strategies, and enabling appropriate treatment intensification.
For people living with suboptimal diabetes (Hbalc greater than 53 mmol/mol) and CKD 3B or earlier (eGFR 30 ml/min and above), please see the referral criteria and pathway in Appendix 1, for guidance (PDF).
Optimise treatment by progressing therapy as appropriate and by improving patient expertise on self-management on the following parameters.
Kathy joined Pinnacle earlier this month as clinical diabetes specialist for Waikato, replacing the role previously held by Anne Waterman.
Read moreBoth dulaglutide (Trulicity™) and Liraglutide (Victoza™) can be initiated for new patients who meet the special authority criteria from 1st July 2025.
Read moreFunding for patients who require a follow-up appointment following HbA1c retest by Awanui Labs.
View detailsA guide for clinical management of type 2 diabetes, to support nurses at all levels to develop their knowledge and clinical reasoning in diabetes care.